# An Unusual Case of Metastatic Gastric Cancer Presenting with Right Heart Failure and Cardiac Metastasis

**Authors:** Ebru Engin Delipoyraz, Maral Martin Mildanoglu, Barış Sürül, Oktay Olmuşçelik, Korhan Erkanlı, Ahmet Bilici

PMC · DOI: 10.3390/medicina61020170 · Medicina · 2025-01-21

## TL;DR

A rare case of metastatic gastric cancer causing right heart failure and cardiac metastasis is presented, highlighting the importance of considering this complication in similar patients.

## Contribution

This case report highlights the rare occurrence of cardiac metastasis from gastric cancer and its presentation as heart failure.

## Key findings

- A 51-year-old male with metastatic gastric cancer presented with right heart failure due to a mass in the right atrium.
- Cardiac metastasis was confirmed through imaging and pathology, and systemic treatment led to regression of other lesions.
- The case emphasizes the need to consider cardiac metastasis in gastric cancer patients with unexplained heart failure.

## Abstract

Cardiac metastasis is rarely detected in oncology practice. Herein we present a rare case of metastatic gastric cancer that metastasized to the right atrium and presented with right heart failure. A 51-year-old male patient with no known chronic disease presented with fatigue, abdominal distension and leg edema for 3 weeks. Physical examination revealed abdominal ascites, tachycardia and pretibial edema. Transthoracic echocardiography (TTE) revealed a hypoechoic, less-mobile mass that almost completely filled the right atrium. Moreover, 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) showed metastatic lesions and a primary tumor-suspicious area in the esophagogastric component. Upper GI endoscopic evaluation performed on the patient revealed an ulcerovegetating mass consistent with gastric adenocarcinoma. A human epidermal growth factor receptor 2 (HER-2) was positiveand programmed death-ligand 1 (PD-L1) combined positive score (CPS) was detected as 15 in immunohistochemistry (IHC). Thereafter, an anticoagulant treatment was started including pembrolizumab and trastuzumab every three weeks, and an oxaliplatin and 5-FU-based chemotherapy regimen was started every two weeks. There was no regression in the cardiac lesion during follow-up; thereafter, there was a significant risk of cardioembolic complications, and a 10 × 7 cm mass filling the right atrium and adhering to the inferior vena cava was resected. The pathology results of the excision material reported gastric carcinoma metastasis. Systemic evaluation performed 3 months later showed regression in primary and metastatic lesions. Cardiac metastases are rare and may not be discovered until autopsy due to the prominence of primary disease findings. Cardiac metastasis, although rare, should be kept in mind in gastric cancer patients presenting with heart failure.

## Linked entities

- **Proteins:** ERBB2 (erb-b2 receptor tyrosine kinase 2), CD274 (CD274 molecule)
- **Chemicals:** oxaliplatin (PubChem CID 9887053), 5-FU (PubChem CID 3385)
- **Diseases:** gastric cancer (MONDO:0001056), gastric adenocarcinoma (MONDO:0005036)

## Full-text entities

- **Genes:** CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}
- **Diseases:** cardioembolic complications (MESH:D000083262), tumor (MESH:D009369), tachycardia (MESH:D013610), edema (MESH:D004487), cardiac lesion (MESH:D006331), Heart Failure (MESH:D006333), abdominal distension (MESH:D000007), fatigue (MESH:D005221), ascites (MESH:D001201), Cardiac Metastasis (MESH:D009362), Gastric Cancer (MESH:D013274), chronic disease (MESH:D002908)
- **Chemicals:** oxaliplatin (MESH:D000077150), 5-FU (MESH:D005472), trastuzumab (MESH:D000068878), 18F-FDG (MESH:D019788), pembrolizumab (MESH:C582435)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11857640/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11857640/full.md

## References

18 references — full list in the complete paper: https://tomesphere.com/paper/PMC11857640/full.md

---
Source: https://tomesphere.com/paper/PMC11857640